Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Other Non-Current Liabilities (2023 - 2024)

Rapport Therapeutics (RAPP) has 2 years of Other Non-Current Liabilities data on record, last reported at $9.4 million in Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities rose 124.57% to $9.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $9.4 million, a 124.57% increase, with the full-year FY2024 number at $9.4 million, up 124.57% from a year prior.
  • Other Non-Current Liabilities reached $9.4 million in Q4 2024 per RAPP's latest filing, up from $4.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for RAPP hit a ceiling of $9.4 million in Q4 2024 and a floor of $4.2 million in Q4 2023.